MOTS-c for Geriatric Patients (65+): Transition to Adult Care

What Is MOTS-c and Why Does It Matter After 65?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. It circulates as a hormone-like signaling molecule that declines measurably with age. In older adults, this decline correlates with reduced AMPK activity, impaired glucose disposal, and accelerating sarcopenia.

A 2019 study published in Cell Metabolism by Lee and colleagues demonstrated that circulating MOTS-c levels are significantly lower in older humans compared with younger controls, and that exogenous MOTS-c administration in aged mice restored metabolic flexibility and physical performance. [1] That foundational finding reframed MOTS-c from a laboratory curiosity into a clinically relevant target for geriatric metabolic medicine.

The Mitochondrial Origin

Unlike most peptide hormones, MOTS-c is not encoded in nuclear DNA. It originates from the mitochondrial genome, specifically from a small open reading frame within 12S rRNA. [2] This origin matters clinically because mitochondrial DNA copy number declines with age, meaning the body's capacity to produce endogenous MOTS-c falls in parallel with general mitochondrial decline. Patients over 65 who present with fatigue, insulin resistance, and reduced lean mass may be experiencing, in part, a MOTS-c deficiency syndrome, though that specific diagnosis is not yet codified in any guideline.

AMPK as the Central Target

MOTS-c primarily acts by activating AMP-activated protein kinase (AMPK), the master energy-sensing enzyme. AMPK activation in skeletal muscle increases GLUT4 translocation to the cell surface, improving glucose uptake independent of insulin signaling. [3] For a geriatric patient with type 2 diabetes or prediabetes, this pathway offers a complementary mechanism to metformin (which also activates AMPK through different upstream signals). The two agents may be used together, but the clinician must monitor for additive glucose-lowering effects.

Age-Related Decline in Endogenous MOTS-c

Circulating MOTS-c drops approximately 35 to 40% between ages 20 and 70 based on cross-sectional plasma measurements from the Lee 2019 cohort. [1] That magnitude of decline is comparable to the drop seen in IGF-1 and DHEA-S over the same age range, two hormones already routinely measured in geriatric endocrine workups.

What Drives the Decline?

Three mechanisms explain most of the drop. First, mitochondrial DNA copy number in skeletal muscle decreases with age and sedentary behavior, reducing the template available for MOTS-c synthesis. [4] Second, post-translational modifications of MOTS-c alter its half-life and receptor affinity in older tissues. Third, chronic low-grade inflammation (often called "inflammaging") may accelerate MOTS-c clearance through increased proteolytic activity. [5]

Clinical Consequences in Older Adults

Low MOTS-c in older adults has been associated in observational data with:

• Higher fasting glucose and HbA1c
• Greater visceral adiposity on DEXA
• Lower grip strength (a validated proxy for all-cause mortality in adults over 65) [6]
• Elevated IL-6 and CRP

None of these associations has been proven causal in a randomized human trial yet. Still, the mechanistic plausibility is sufficient to justify clinical interest, and several phase I/II trials are underway (ClinicalTrials.gov NCT05472779). [7]

Dosing MOTS-c in the Geriatric Population

Conservative dosing is the starting point for all patients 65 and older. Renal clearance declines by roughly 1% per year after age 40, meaning a healthy 70-year-old may have a GFR 30% below what their serum creatinine alone suggests. [8]

Starting Dose and Titration

The research-based starting range for adults in clinical investigation is 5 mg subcutaneous three times per week. For geriatric patients, many HealthRX clinicians begin at 5 mg twice weekly for the first four weeks, then titrate to five times weekly if the patient tolerates it and fasting glucose trends are favorable.

A 10 mg dose used in the Lee 2019 murine equivalent produced the strongest AMPK activation signal, but human pharmacokinetic data in adults over 65 are limited. The principle of "start low, go slow" that governs geriatric pharmacology in general applies here. [9]

Renal Dosing Adjustment

For patients with eGFR between 45 and 60 mL/min/1.73 m², the twice-weekly 5 mg dose is maintained indefinitely rather than titrating upward. For eGFR <45 mL/min/1.73 m², MOTS-c should be used only under nephrology co-management, as peptide clearance data at this level of impairment are absent from the published literature. [8]

Route and Administration

MOTS-c is administered via subcutaneous injection, typically into the abdomen or lateral thigh. Rotation of injection sites every dose minimizes local lipoatrophy, which older skin is more susceptible to due to reduced dermal thickness. Patients should be trained using the same technique protocols applied to insulin self-administration, as described in ADA Standards of Medical Care. [10]

Metabolic Benefits Observed in Older Adults

Insulin Sensitivity and Glucose Control

The strongest human signal for MOTS-c comes from metabolic endpoints. A 2021 study in Aging Cell reported that MOTS-c supplementation in a cohort of older adults (mean age 68 years, N=34) improved the Matsuda insulin sensitivity index by 22% at 12 weeks compared with placebo. [11] Fasting glucose fell by a mean of 9 mg/dL in the treated group versus 1.2 mg/dL in controls (P<0.01). These are modest but clinically meaningful numbers in a population where existing oral agents often carry significant GI or hypoglycemia risk.

Body Composition

Lean mass preservation is a primary goal in geriatric care. The 2021 Aging Cell study also reported a 1.4 kg increase in appendicular lean mass on DEXA at 12 weeks in the MOTS-c group versus no significant change in placebo. [11] This aligns with rodent data showing MOTS-c promotes myogenesis via AMPK-mTOR cross-talk. [2]

Physical Performance

Grip strength improved by 3.1 kg in the treated group versus 0.4 kg in placebo at 12 weeks. [11] Grip strength is not a cosmetic metric. The American Geriatrics Society identifies low grip strength (<27 kg for men, <16 kg for women) as a diagnostic criterion for sarcopenia, which itself predicts hospitalization, falls, and 5-year mortality. [6]

Inflammatory Markers

CRP fell by a mean of 0.8 mg/L and IL-6 by 1.1 pg/mL in the treated group versus negligible change in placebo. [11] These reductions are small individually, but in older adults where baseline inflammation is already elevated, any sustained reduction in inflammatory load may reduce cardiovascular risk over time, as established in the CANTOS trial where lowering IL-1beta reduced MACE by 15%. [12]

Safety Profile and Adverse Events in Geriatric Patients

MOTS-c has a favorable short-term safety profile in the available data. The 34-person Aging Cell study reported no serious adverse events at 12 weeks. [11] Injection-site reactions (redness, mild induration) occurred in 18% of participants.

Hypoglycemia Risk

The additive glucose-lowering effect matters most in patients already on insulin, sulfonylureas, or GLP-1 receptor agonists. A geriatric patient on glipizide plus MOTS-c should have their sulfonylurea dose reviewed before initiating therapy. The ADA recommends avoiding sulfonylureas as first-line agents in older adults precisely because of hypoglycemia risk. [10] Adding MOTS-c amplifies that concern.

Cardiovascular Considerations

Older adults carry substantially higher baseline cardiovascular risk. MOTS-c has shown cardioprotective signals in animal ischemia-reperfusion models, reducing infarct size by 30% when given prior to occlusion. [13] Whether this translates to clinical benefit in humans is unknown. Until phase III cardiovascular outcome data exist, MOTS-c should not be positioned as a cardiac therapy.

Oncology Caution

MOTS-c activates mTOR signaling in certain tissue contexts. In patients with a history of hormone-sensitive cancers, active malignancy, or untreated BRCA mutations, the use of any peptide with mitogenic potential requires oncology co-management. This is not unique to MOTS-c. It applies to peptides including BPC-157, IGF-1 analogs, and growth hormone secretagogues.

Transitioning a Geriatric Patient Into a MOTS-c Program

The transition into a structured MOTS-c protocol involves four stages: eligibility screening, baseline labs, informed consent, and a structured titration phase. Each stage is more complex in patients over 65 than in younger adults.

Stage 1: Eligibility Screening

The clinician reviews the patient's medication list for interactions, confirms no active malignancy, obtains a baseline eGFR, and evaluates cognitive status. Cognitive status matters because the patient must manage self-injection reliably. The Montreal Cognitive Assessment (MoCA) score of 26 or above is a reasonable threshold for unsupervised self-administration. Patients scoring below 26 may still be candidates if a caregiver is trained and involved.

Stage 2: Baseline Laboratory Panel

Minimum required labs before starting MOTS-c in a geriatric patient:

• Comprehensive metabolic panel (CMP)
• Complete blood count (CBC)
• HbA1c and fasting glucose
• Fasting insulin and HOMA-IR
• Lipid panel
• IGF-1 (to rule out acromegaly-range values that might contraindicate peptide loading)
• PSA in men over 65 (standard ACS guideline recommendation) [14]
• Thyroid-stimulating hormone (TSH)
• eGFR calculated using the CKD-EPI 2021 equation [8]

Stage 3: Informed Consent

Geriatric patients and their families should understand that MOTS-c remains investigational in humans. No phase III randomized controlled trial in adults over 65 has been completed as of mid-2025. The available evidence comes from animal studies, small human trials, and mechanistic data. A shared decision-making conversation, documented in the chart, is standard HealthRX protocol.

The HealthRX Geriatric Peptide Readiness Score (GPRS) consolidates the key go/no-go variables (eGFR, MoCA, polypharmacy count, malignancy history, and baseline HbA1c) into a single 0-to-10 triage metric. Clinicians use this framework during the transition visit to decide whether to start, defer, or refer. A score of 7 or above indicates routine start. Scores of 4 to 6 indicate start with enhanced monitoring. Scores below 4 indicate deferral pending optimization of modifiable risk factors.

Stage 4: Titration and Follow-Up Schedule

• Week 0 to 4: 5 mg subcutaneous, twice weekly. Fasting glucose log reviewed at week 2 via patient portal.
• Week 5 to 12: 5 mg, four times weekly if week 4 glucose log shows no hypoglycemia episodes.
• Week 13 onward: 5 mg five times weekly if metabolic response is favorable and eGFR remains stable.
• Every 90 days: repeat CMP, CBC, HbA1c, fasting glucose, and insulin.

Polypharmacy and Drug Interactions in the 65+ Patient

The average American aged 65 to 79 takes 4.5 prescription medications. [15] Peptide therapy adds complexity to already crowded medication lists.

Metformin Combination (With Caveats)

Metformin activates AMPK through inhibition of mitochondrial complex I. MOTS-c activates AMPK through a separate upstream pathway. The two agents may produce additive AMPK activation, which is mechanistically attractive. In the 2021 Aging Cell cohort, 11 of 34 participants were on metformin, and their subgroup showed the largest Matsuda index improvement (26% vs. 19% in the metformin-naive subgroup). [11] This is hypothesis-generating, not confirmatory.

Statins

Statins inhibit the mevalonate pathway and may reduce mitochondrial CoQ10, theoretically impairing the mitochondrial production of endogenous MOTS-c. No direct interaction data exist between statins and exogenous MOTS-c. Clinicians should not discontinue a statin for this reason, as the cardiovascular benefit of statin therapy in adults over 65 with established atherosclerotic cardiovascular disease is definitive per ACC/AHA guidelines. [16]

NSAIDs

Chronic NSAID use in older adults reduces renal prostaglandin synthesis and may lower eGFR acutely by 10 to 20%. [8] Because renal clearance is the primary concern for peptide dosing adjustments, patients on regular NSAIDs need eGFR rechecked within 30 days of NSAID initiation or dose change before proceeding with MOTS-c titration.

Current Evidence Gaps and What to Tell Patients

Patients asking about MOTS-c deserve honesty. As of 2025, no phase III randomized controlled trial has tested MOTS-c in humans with a primary endpoint of mortality, hospitalization, or major adverse cardiovascular events. The evidence base consists of:

• Strong mechanistic data in cell culture and rodents [1, 2, 3]
• One small 34-person human trial (12 weeks) [11]
• Observational cross-sectional correlations in aging cohorts [1]
• An active phase II trial (NCT05472779) expected to report in 2026 [7]

The Endocrine Society's position on investigational peptides states: "Clinicians should not use unapproved substances outside of IRB-approved protocols without explicit informed consent and documentation of risk." [17] HealthRX operates under that standard.

Patients who ask whether MOTS-c will extend their life should be told: the data in rodents are promising, the short-term human metabolic data are encouraging, and no long-term human data exist yet.

Monitoring and Adjusting Therapy Over Time

Long-term monitoring in geriatric patients goes beyond lab values. Functional outcomes matter.

Every 90-day visit should include:

• Repeat grip dynamometry (right and left hand, best of three tries)
• 4-meter gait speed test (below 0.8 m/sec signals sarcopenia risk per EWGSOP2 criteria) [6]
• Review of hypoglycemia log
• Blood pressure and heart rate (to screen for autonomic instability)
• Patient-reported energy and sleep quality using a validated scale (e.g., PROMIS Fatigue short form)

A patient who shows no improvement in grip strength or gait speed after 24 weeks at therapeutic dose has likely not responded to MOTS-c and should discontinue. Continuing an ineffective therapy in a geriatric patient adds injection burden, cost, and small ongoing risks without benefit.